Heparosan-Derived Heparan Sulfate/Heparin-Like Compounds: One Kind of Potential Therapeutic Agents

Medicinal Research Reviews

Volumn 33, Issue 3, 2013, Pages 665-692

  Li, Pingli ^a   Sheng, Juzheng ^a,b   Liu, Yuhong ^a   Li, Juan ^a   Liu, Jian ^b   Wang, Fengshan ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Heparan sulfate; Heparin; Heparosan; Heparosan derivatives

Indexed keywords

ANTICOAGULANT AGENT; ANTIVIRUS AGENT; CELLULOSE SULFATE; EPI HEPAROSAN N,OS; EPI HEPAROSAN OS; FONDAPARINUX; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARAN SULFATE; HEPARIN; HEPAROSAN N,OS; HEPAROSAN OS; LOW MOLECULAR WEIGHT HEPARIN; NEOHEPARIN; PENTASACCHARIDE; POLYMETHYLENEHYDROQUINONE; POLYSTYRENESULFONATE CALCIUM; PRO 2000; RECOMPARIN; SULFAMINOHEPAROSAN; UNCLASSIFIED DRUG;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BIOSYNTHESIS; CHEMICAL MODIFICATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; ENZYME MODIFICATION; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; NONHUMAN; PAPILLOMAVIRUS INFECTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-HIV AGENTS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BACTERIAL CAPSULES; CATTLE; DISACCHARIDES; ESCHERICHIA COLI; HEPARIN; HEPARITIN SULFATE; PAPILLOMAVIRIDAE; SIMPLEXVIRUS;

EID: 84876084809     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21263     Document Type: Article

References (140)

1. Liu RP, Liu J. Enzymatic synthesis of heparin. In: Singh OV, Harvey SP, Eds. Sustainable Biotechnology. Dordrecht: Springer Science+Business Media B.V.;2010. p 259-277.
2. Smith SA. The cell-based model of coagulation. J Vet Emerg Crit Car 2009;19:3-10.
3. Stringer SE. The role of heparan sulphate proteoglycans in angiogenesis. Biochem Soc Trans 2006;34:451-453.
4. Mahtouk K, Cremer FW, Rème T, Jourdan M, Baudard M, Moreaux J, Requirand G, Fio G, Vos JD, Moos M, Quittet P, Goldschmidt H, Rossi JF, Hose D, Klein B. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 2006;25:7180-7191.
5. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol 2006;6:633-643.
6. Henry-Stanley MJ, Hess DJ, Erlandsen SL, Wells CL. Ability of the heparan sulfate proteoglycan syndecan-1 to participate in bacterial translocation across the intestinal epithelial barrier. Shock 2005;24:571-576.
7. Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 2007;46:1759-1768.
8. Urbinati C, Nicoli S, Giacca M, David G, Fiorentini S, Caruso A, Alfano M, Cassetta L, Presta M, Rusnati M. HIV-1 Tat and heparan sulfate proteoglycan interaction: A novel mechanism of lymphocyte adhesion and migration across the endothelium. Blood 2009;114:3335-3342.
9. Lambaerts K, Wilcox-Adelman SA, Zimmermann P. The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr Opin Cell Biol 2009;21:662-669.
10. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 19:64S-94S.
11. Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence. Thromb Haemost 2009;102:258-267.
12. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008; 2:743-752.
13. Linhardt RJ, Dordick JS, Deangelis PL, Liu J. Enzymatic synthesis of glycosaminoglycan heparin. Semin Thromb Hemost 2007;33:453-465.
14. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999;25:5-16.
15. De Kort M, Buijsman RC, Van Boeckel CAA. Synthetic heparin derivatives as new anticoagulant drugs. DDT 2005;10:769-779.
16. Deangelis PL. Evolution of glycosaminoglycans and their glycosyltransferases: Implication for the extracellular matrices of animals and the capsules of pathogenic bacteria. The Anat Rec 2002;268:317-326.
17. Vann WF, Schmidt MA, Barbara J, Klaus J. The structure of the capsular polysaccharide (K5 antigen) of urinary-tract-infective Escherichia coli 010:K5:H4. A polymer similar to desulfo-heparin. Eur J Biochem 1981;116:359-364.
18. DeAngelis PL, Gunay NS, Toida T, Mao W, Linhardt RJ. Identification of the capsular polysaccharides of Type D and F Pasteurella multocida as unmodified heparin and chondroitin, respectively. Carbohydr Res 2002;337:1547-1552.
19. Chavaroche AAE, Springer J, Kooy F, Boeriu C, Eggink G. In vitro synthesis of heparosan using recombinant Pasteurella multocida heparosan synthase PmHS2. Appl Microbiol Biotechnol 2010;85:1881-1891.
20. Hodson N, Griffiths G, Cook N, Pourhossein M, Gottfridson E, Lind T, Lidholt K, Roberts IS. Identification that KfiA, a protein essential for the biosynthesis of the Escherichia coli K5 capsular polysaccharide, is an α-UDP-GlcNAc glycosyltransferase. J Biol Chem 2000;275:27311-27315.
21. Petit C, Rigg GP, Pazzani C, Smith A, Sieberth V, Stevens M, Boulnois G, Jann K, Roberts IS. Region 2 of the Escherichia coli K5 capsule gene cluster encoding proteins for biosynthesis of the K5 polysaccharide. Mol Microbiol 1995;17:611-620.
22. Chen M, Bridges A, Liu J. Determination of the substrate specificities of N-acetyl-D-glucosaminyltransferase. Biochemistry 2006;45:12358-12365.
23. DeAngelis PL, White CL. Identification of a distinct, cryptic heparosan synthase from Pasteurella multocida types A, D, and F. J Bacteriol 2004;186:8529-8532.
24. Sismey-Ragatz AE, Green DE, Otto NJ, Rejzek M, Field RA, Deangelis PL. Chemoenzymatic synthesis with distinct Pasteurella heparosan synthases: Monodisperse polymers and unnatural structures. J Biol Chem 2007;282:28321-28327.
25. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007;446:1030-1037.
26. Liu J, Pedersen LC. Anticoagulant heparin sulfate: Structural specificity and biosynthesis. Appl Microbiol Biotechnol 2007;74:263-272.
27. Pinhal MAS, Smith B, Olson S, Aikawa JI, Kimata K, Esko JD. Enzyme interactions in heparan sulfate biosynthesis: Uronosyl 5-epimerase and 2-O-sulfotransferase interact in vivo. PNAS 2001;98:12984-12989.
28. Peterson S, Frick A, Liu J. Design of biologically active heparan sulfate and heparin using an enzyme-based approach. Nat Prod Rep 2009;26:610-627.
29. Lindahl U, Li JP, Kusche-Gullberg M, Salmivirta M, Alaranta S, Veromaa T, Emeis J, Roberts I, Talyor C, Oreste P, Zoppetti G, Naggi A, Torri G, Casu B. Generation of "Neoheparin" from E. coli K5 capsular polysaccharide. J Med Chem 2005;48:349-352.
30. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359: 938-949.
31. Viles-Gonzalez JF, Anand SX, Zafar MU, Fuster V, Badimon JJ. Tissue factor coagulation pathway: A new therapeutic target in atherothrombosis. J Cardiovasc Pharmacol 2004;43:669-676.
32. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: Structure, biology and involvement in disease. J Pathol 2006;208:327-339.
33. Ma Q, Tobu M, Schultz C, Jeske W, Hoppensteadt D, Walenga J, Cornelli U, Lee J, Linhardt R, Hanin I, Eareed J. Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Thromb Res 2007;119:653-661.
34. Kuberan B, Lech MZ, Beeler DL, Wu ZL, Rosenberg RD. Enzymatic synthesis of antithrombinIII- binding heparin sulfate pentasaccharide. Nat Biotechnol 2003;21:1343-1346.
35. Chen JH, Jones CL, Liu J. Using an enzymatic combinatorial approach to identify anticoagulant heparan sulfate structures. Chem Biol 2007;14:986-993.
36. Kakuta Y, Li L, Pedersen LC, Pedersen LG, Negishi M. Heparan sulphate N-sulphotransferase activity: Reaction mechanism and substrate recognition. Biochem Soc Trans 2003;31:331-334.
37. Chen JH, Avci FY, Munoz EM, McDowell LM, Chen M, Pedersen LC, Zhang LJ, Linhardt RJ, Liu J. Enzymatic redesigning of biologically active heparan sulfate. J Biol Chem 2005;280:42817-42825.
38. Munoz E, Xu D, Kemp M, Zhang F, Liu J, Linhardt RJ. Affinity, kinetic, and structural study of the interaction of 3-O-sulfotransferase isoform 1 with heparan sulfate. Biochemistry 2006;45:5122-5128.
39. Casu B, Grazioli G, Razi N, Guerrini M, Naggi A, Torri G, Oreste P, Tursi F, Zoppetti G, Lindahl U. Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohyd Res 1994;263:271-284.
40. Maddineni J, Jeske WP, Baltasar F, Cornelli U, Manoni M, Hoppensteadt DA, Fareed J. Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: Flow cytometric analysis. Clin Appl Thromb Hemost 2006;12:311-317.
41. Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 2009;102:823-828.
42. Bartlett AH, Hayashida K, Park PW. Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol Cell 2007;24:153-166.
43. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008; 22:743-752.
44. Lever R, Samilbegovic A, Page CP. Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity. Eur J Pharmacol 2010;630:137-144.
45. Ramyaa Lakshmi TS, Shanmugasundaram N, Shanmuganathan S, Karthikeyan K, Meenakshi J, Babu M. Controlled release of 2, 3 desulfated heparin exerts its anti-inflammatory activity by effectively inhibiting E-selectin. J Biomed Mater Res A 2010;95:118-128.
46. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002;110:127-136.
47. Wan JP, Mu JS, Zhu HS, Geng JG. N-desulfated non-anticoagulant heparin inhibits leukocytes adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo. Inflamm Res 2002;51:435-443.
48. Gao Y, Li N, Fei R, Chen Z, Zheng S, Zeng X. P-Selectin-mediated acute inflammation can be blocked by chemically modified heparin, RO-heparin. Mol Cells 2005;19:350-355.
49. De Paz JL, Moseman EA, Noti C, Polito L, Von Andrian UH, Seeberger PH. Profiling heparin-chemokine interactions using synthetic tools. ACS Chem Biol 2007;2:735-744.
50. Spillmann D, Witt D, Lindahl U. Defining the ilterleukin-8-binding domain of heparan sulfate. The Journal of Biological Chemistry 1998;273:15487-15493.
51. Gori AM, Attanasio M, Gazzini A, Rossi L, Lucarini L, Miletti S, Chini J, Manoni M, Abbate R, Gensini GF. Cytokine gene expression and production by human LPS-stimulated mononuclear cells are inhibited by sulfated heparin-like semi-synthetic derivatives. J Thromb Haemost 2004;2:1657-1662.
52. Staples KJ, Smallie T, Williams LM, Foey A, Burke B, Foxwell BMJ, Ziegler-Heitbrock L. IL-10 induces IL-10 in primary human monocyte-derived macrophages via the transcription factor Stat3. J Immunol 2007;178:4779-4785.
53. Mocco J, Shelton CE, Sergot P, Ducruet AF, Komotar RJ, Otten ML, Sosunov SA, MacArthur RB, Kenndedy TP, Connolly E, Sander J. O-desulfated heparin improves outcome after rat cerebral ischemia/reperfusion injury. Neurosurgery 2007;61:1297-1304.
54. 2+ loading during simulated ischemia and decreases reperfusion injury. Am J Physiol Heart Circ Physiol 2010;298:H102-111.
55. Zhang ZG, Zhang QZ, Cheng YN, Ji SL, Du GH. Antagonistic effects of ultra-low-molecular-weight heparin against cerebral ischemia/reperfusion injury in rats. Pharmacol Res 2007;56:350-355.
56. Dorweiler B, Pruefer D, Andrasi TB, Maksan SM, Schmiedt W, Neufang A, Vahl CF. Ischemia-reperfusion injury: Pathopysiology, pathophysiology and clinical implication. Eur J Trauma Emerg Surg 2007;33:600-612.
57. Collino M, Csatiglia S, Manoni M, Salsini L, Chini J, Masini E, Fantozzi R. Effects of a semi-synthetic N-, O-sulfated glycosaminoglycan K5 polysaccharide derivative in a rat model of cerebral ischaemia/reperfusion injury. Thromb Haemost 2009;102:837-845.
58. Ceccarelli M, Bani D, Cinic L, Nistri S, Uliva C, Ragazzo E, Vannacci A, Manoni M, Gori AM, Abbate R, Gensini GF, Masini E. Anti-inflammatory effects of low molecular weight heparin derivatives in a rat model of carrageenan-induced pleurisy. J Cell Mol Med 2009;13:2704-2712.
59. Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence. Thromb Haemost 2009;102:258-267.
60. Niers TMH, Klerk CPW, DiNisio M, Van Noorden CJF, Buller HR, Reitsma PH, Richel DJ. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007;61:195-207.
61. Kakkar AK. Low-molecular-weight heparin and survival in patients with malignant disease. Cancer Control 2005;12:22-30.
62. Noble SIR. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: A case series of sixty two patients. Palliative Med 2007;21:473-476.
63. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005;6:401-410.
64. Prandoni P, Falanga A, Piccioli A. Cancer, thrombosis and heparin-induced thrombocytopenia. Thromb Res 2007;120:137-140.
65. Connolly GC, Khorana AA. Risk stratification for cancer-associated venous thromboembolism. Best Pract Res Clin Haematol 2009;22:35-47.
66. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008;99:807-818.
67. Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, Schunemann HJ. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cancer 2008;113:1685-1694.
68. Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulation as cancer treatment: Impact on survival and bleeding complications. Cancer 2007;10:1149-1161.
69. Rusnati M, Oreste P, Zoppetti G, Presta M. Biotechnological engineering of heparin/heparan sulphate: A novel area of multi-target drug discovery. Curr Pharma Design 2005;11:2489-2499.
70. Rickles FR, Patierno S, Fernandze PM. Tissue factor, thrombin, and cancer. Chest 2003;124:58-68.
71. Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992;313:355-364.
72. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45.
73. Tassi E, Wellstein A. The anbiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal. Semin Oncol 2006;33(6 Suppl 11):S50-56.
74. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Ruanati M. Fibroblast growth factor/fibroblast factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16:159-178.
75. Whitworth MK, Backen AC, Clamp AR, Wilson G, McVey R, Friedl A, Rapraeger AC, David G, McGown A, Slade RJ, Gallagher JT, Javson GC. Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res 2005;11:4282-4288.
76. Zhang WQ, Swanson R, Xiong Y, Richard B, Olson ST. Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: Evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains. J Biol Chem 2006;281:37302-37310.
77. Leali D, Alessi P, Coltrini D, Rusnati M, Zetta L, Presta M. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides. Curr Pharm Des 2009;15:3577-3589.
78. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991;64:841-848.
79. Fannon M, Forsten KE, Nugent MA. Potenitiation and inhibition of bFGF binding by heparin: A model for regulation of cellular response. Biochemistry 2000;39:1434-1445.
80. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E, Leder P. Heparin is required for cell-free binding of basic fibroblast growth factors to a soluble receptors and for mitogenesis in whole cells. Mol Cell Biol 1992;12:240-247.
81. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, Ribatti D, Rusnati M, Presta M. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 2001;276:37900-37908.
82. Borgenstrom M, Jalkanen M, Salmivirta M. Sulfated derivatives of Escherichia coli K5 polysaccharides as modulators of fibroblast growth factor signaling. J Biol Chem 2003;278:49882-49889.
83. Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, Leali D, Urbinati C, Bugatti A, Ronca R, Nicoli S, Moroni E, Stabile H, Camozzi M, Hernandez GA, Mitola S, Dell'sEra P, Rusnati M, Ribatti D. Antiangiogenic activity of semisynthetic biotechnological heparins: Low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. Arterioscler Thromb Vasc Biol 2005;25:71-76.
84. Kreuger J, Spillman D, Li JP, Lindahl U. Interactions between heparan sulfate and proteins: The concept of specificity. JCB 2006;174:323-327.
85. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. Heparin structure and interactions with basic fibroblast growth factor. Science 1996;271:1116-1120.
86. Sugaya N, Habuchi H, Nagai N, Ashikari-Hada S, Kimata K. 6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture. J Biol Chem 2008;283:10366-10376.
87. Fairweather JK, Karoli T, Liu L, Bytheway I, Ferro V. Synthesis of heparan mimetic disaccharide with a conformationally locked residue from a common intermediate. Carbohyd Res 2009;334:2394-2398.
88. Pellegrini L. Role of heparan sulfate in fibroblast growth factor signaling: A structure view. Curr Opin Struc Biol 2001;11:629-634.
89. Simka M, Urbanek T. Anti-metastasis activities of heparins. J Cancer Mol 2009;5:3-8.
90. Stevenson JL, Varki A, Borsig L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res 2007; 120(Suppl 2):S107-111.
91. Borgenstrom M, Warri A, Hiilesvuo K, Kakonen R, Kakonen S, Nissinen L, Pihlavisto M, Marjamaki A, Vlodaysky I, Naggi A, Torri G, Casu B, Veromaa T, Salmivirta M, Elenius K. O-sulfated bacterial polysaccharide with low anicoagulant activity inhibit metastasis. Semi Thromb Hemost 2007;33:547-556.
92. Peterson SB, Liu J. Unraveling the specificity of heparanase utilizing synthetic substrates. J Biol Chem 2010;285:14504-14513.
93. Crublet E, Andrieu JP, Vives RR, Lortat-Jacob H. The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site. J Biol Chem 2008;283:15193-15200.
94. Crim RL, Auset SA, Feldman SA, Mostowski HS, Beeler JA. Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity. J Virol 2007;81:261-271.
95. Barth H, Schnober EK, Zhang FM, Linhardt RJ, Depla E, Boson B, Cosset FL, Patel AH, Blum HE, Baumert TF. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Viro 2006;80:10579-10590.
96. Knappe M, Bodevin S, Selinka HC, Spillmann D, Streeck RE, Chen XS, Lindahl U, Sapp M. Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J Biol Chem 2007;282:27913-27922.
97. O'Donnell CD, Shukla D. The importance of heparan sulfate in Herpesvirus infection. Virol Sin 2008;23:383-393.
98. Urbinati C, Chiodelli P, Rusnati M. Polyanionic drugs and viral oncogenesis: A novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules 2008;13:2758-2785.
99. Rusnati M, Vicenzi E, Donalisio M, Oreste P, Landolfo S, Lembo D. Sulfated K5 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides. Pharmacol Therapeut 2009;123:310-322.
100. Tilton JC, Doms RW. Entry inhibitors in the treatment of HIV-1 infection. Antivir Res 2010; 85:91-100.
101. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Ann Rev Immunol 1999;17:657-700.
102. Gallay P. Syndecans and HIV-1 pathogenesis. Microbes Infect 2004;6:617-622.
103. Vives RR, Imberty A, Sattentau QJ, Lortat-Jacob H. Heparan sulfate targets the envelope glycoprotein gp120 coreceptor binding site. J Biol Chem 2005;280:21353-21357.
104. Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Pavone Cossut MR, Scoglio A, Collacchi B, Nappi F, Macchia I, Bellino S, Francavilla V, Caputo A, Barillari G, Magnani M, Laguardia ME, Cafaro A, Titti F, Monini P, Ensoli F, Ensoli B. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol 2009;182:2888-2897.
105. Bugatti A, Urbinati C, Ravelli C, De Clercq E, Liekens S, Rusnati M. Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus Type 1 Tat and gp120 proteins. Antimicrob Agents Chemother 2007;51:2337-2345.
106. Ai J, Xin X, Zheng M, Wang S, Peng S, Li J, Wang L, Jiang H, Geng M. A triad of Lys12, Lys41, Arg78 spatial domain, a novel identified heparin binding site on Tat protein, facilitates Tat-driven cell adhesion. PLoS ONE 2008;3:e2662. doi:10.1371/journal.pone.0002662.
107. Vicenzi E, Gatti A, Ghezzi S, Oreste P, Zoppetti G, Poli G. Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives. AIDS 2003;17:177-181.
108. Lu CX, Li J, Sun YX, Qi X, Wang QJ, Xin XL, Geng MY. Sulfated polymannuroguluronate, a novel anti-AIDS drug candidate, inhibits HIV-1 Tat-induced angiogenesis in Kaposi's sarcoma cells. Biochem Pharmacol 2007;74:1330-1339.
109. Urbinati C, Bugatti A, Oreste P, Zoppetti G, Waltenberger J, Mitola S, Ribatti D, Presta M, Rusnati M. Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. FEBS Lett 2004;568:171-177.
110. Ghosh T, Chattopadhyay K, Marschall M, Karmakar P, Mandal P, Ray B. Focus on antivirally active sulfated polysaccharides: From structure-activity analysis to clinical evaluation. Glycobiology 2009;19:2-15.
111. Raghuraman A, Tiwari V, Zhao Q, Shukla D, Debnath AK, Desai UR. Viral inhibition studies on sulfated lignin, a chemically modified biopolymer and a potential mimic of heparan sulfate. Biomacromolecules 2008;8:1759-1763.
112. Wang SC, Bligh SWA, Shi SS, Wang ZT, Zhu ZB, Crowder J, Branford-White C, Vella C. Structural features and anti-HIV-1 activity of novel polysaccharide from red algae Grateloupia longifolia and Grateloupia filicina. Int J Biol Macromol 2007;41:369-375.
113. Queiroz KCS, Mediros VP, Queiroz LS, Abreu LR, Rocha HAO, Ferreira CV, Juca MB, Aoyama H, Leite EL. Inhibition of reverse transcriptase activity of HIV by polysaccharides of brown algae. Biomed Pharmacother 2008;62:303-307.
114. Huskens D, Vermeire K, Profy AT, Schols D. The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antivir Res 2009;84:38-47.
115. Dammme LV, Govinden R, Mirembe FM, Guedou F, Slolmon S, Becker ML, Pradeep BS, Krishna AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Eng J Med 2008;359:463-472.
116. Skoler-Karpoff S, Ramjee G, Ahmed K, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, Kock AD, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomized, double-blind, placebo-controlled trail. Lancet 2008;372:1977-1987.
117. Arduino PG, Porter SR. Herpes simplex virus type 1 infection: Overview on relevant clinico-pathological features. J Oral Pathol Med 2008;37:107-121.
118. Kwon H, Bai Q, Baek HJ, Felmet K, Burton EA, Goins WF, Cohen JB, Glorioso JC. Soluble V domain of nectin-1/HveC enables entry of herpes simplex virus type 1 (HSV-1) into HSV-resistant cells by binding to viral glycoprotein D. Journal Virol 2006;80:138-148.
119. Campadelli-Fiume G, Amasio M, Avitabile E, Cerretani A, Forghieri C, Gianni T, Menotti L. The multipartite system that mediates entry of herpes simplex virus into the cell. Rev Med Virol 2007;17:313-326.
120. Tiwari V, O'Dannell C, Copeland RJ, Scarlett T, Liu J, Shukla D. Soluble 3-O-sulfated heparan sulfate can trigger herpes simplex virus type 1 entry into resistant Chinese hamster ovary (CHO-K1) cells. J Gen Virol 2007;88:1075-1079.
121. Spear PG, Longnecker R. Herpesvirus entry: An update. J Virol 2003;77:10179-10185.
122. Feyzi E, Trybala E, Bergström T, Lindahl U, Spillmann D. Structural requirement of heparan sulfate for interaction with herpes simplex virus type 1 virions and isolated glycoprotein C. J Biol Chem 1997;272:24850-24857.
123. Mardberg K, Trybala E, Glorioso JC, Bergstrom T. Mutational analysis of the major heparan sulfate-binding domain of herpes simplex virus type-1 glycoprotein C. J Gen Virol 2001;82:1941-1950.
124. Laquerre S, Argnani R, Anderson DB, Zucchini S, Manservigi R, Glorioso JC. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J Virol 1998;72:6119-6130.
125. Copeland R, Balasubramaniam A, Tiwari V, Zhang F, Bridges A, Linhardt RJ, Shukla D, Liu J. Using a 3-O-sufated heparin octasaccharide to inhibit the entry of herpes simplex virus-1. Biochemistry. 2008;47:5774-5783.
126. Hu YP, Lin SY, Huang CY, Zulueta MML, Liu JY, Chang W, Hung SC. Synthesis of 3-O-sulfonated heparan sulfate octasaccharides that inhibit the herpes simplex virus type 1 host-cell interaction. Nat Chem 2011;3:557-563.
127. Cheshenko N, Keller MJ, MasCasullo V, Jarvis GA, Cheng H, John M, Li JH, Hogarty K, Anderson RA, Waller DP, Zaneveld LJD, Profy AT, Klotman ME, Herold BC. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother 2004;48:2025-2036.
128. Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: A double-blind placebo-controlled trail. JID 2006;193:27-35.
129. Pinna D, Oreste P, Coradin T, Kajaste-Rudnitski A, Ghezzi S, Zoppetti G, Rotola A, Argnani R, Poli G, Manservigi R, Vicenzi E. Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide. Antimicrob Agents Chemother 2008;52:3078-3084.
130. Hagner-McWhirter A, Lindahl U, Li JP. Biosynthesis of heparin/heparan sulphate: Mechanism of epimerization of glucuronyl C-5. Biochem J 2000;347:69-75.
131. Mcmurray HR, Nguyen D, Westbrook TF, Mcance DJ. Biology of human papillomaviruses. Int J Exp Path. 2001;82:15-33.
132. Yoon CS, Kim KD, Park SN, Cheong SW. α6 integrin is the main receptor of human papillomavirus type 16 VLP. Biochem and Bioph Res Co 2001;283:668-673.
133. Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 2003;77:13125-13135.
134. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM. Role of heparan sulfate in attachment to and infection of murine female genital tract by human papillomavirus. J Virol 2009;83:2067-2074.
135. Pujol CA, Carlucci MJ, Matulewicz MC, Damonte EB. Natural sulfated polysaccharides for prevention and control of viral infections. The Heterocycl Chem 2007;11:259-281.
136. Lembo D, Donalisio M, Rusnati M, Bugatti A, Cornaglia M, Cappello P, Giovarelli M, Oreste P, Landolfo S. Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus. Antimicrob Agents Ch 2008;52:1374-1381.
137. Bousarghin L, Touzé A, Combita-Rojas AL, Coursaget P. Positively charged sequences oh human papillomavirus type 16 capsid proteins are sufficient to mediate gene transfer into target cells via the heparan sulfate receptor. J Gen Virol 2003;84:157-164.
138. Mercorelli B, Oreste P, Sinigalia E, Muratore G, Lembo D, Palu G, Loregian A. Sulfated derivatives of Escherichia coli K5 capsular polysaccharide are potent inhibitiors of human cytomegalovirus. Antimicrob Agents Ch 2010;54:4561-4567.
139. Wang ZY, Dordick JS, Linhardt RJ. Escherichia coli K5 heparosan fermentation and improvement by genetic engineering. Bioeng Bugs 2011;2:1-5.
140. Schwartz LB. Heparin comes clean. N Engl J Med 2008;358:2505-2509.